Advertisement

Ipilimumab Shows Impressive Activity After HSCT Failure

The immunotherapy ipilimumab (Yervoy), showed impressive activity in patients with hematologic malignancies who experienced relapse after receiving a hematopoietic stem cell transplant (HSCT). These patients have limited treatment options and a poor prognosis.

 Medscape Oncology

click me